Fate Therapeutics (FATE) Assets Average (2013 - 2026)
Fate Therapeutics' (FATE) quarterly Assets Average came in at $301.9 million in Q1 2026, down 28.06% YoY from $419.7 million in Q1 2025, and down 8.87% on a QoQ basis from $331.3 million in Q4 2025.
Fate Therapeutics (FATE) Assets Average (2013 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 14 years of Assets Average data on file, last reported at $301.9 million in Q1 2026.
- Quarterly Assets Average fell 28.06% year-over-year to $301.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $301.9 million (down 28.06% YoY) and the FY2025 annual result came in at $379.8 million, down 19.78% from the prior year.
- Assets Average retreated to $301.9 million in Q1 2026, from $331.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $889.9 million in Q1 2022 to a low of $301.9 million in Q1 2026.
- A 5-year average of $556.2 million and a median of $538.1 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average climbed 6.68% — and 2025, when it slumped 30.13%.
- Tracing FATE's Assets Average over 5 years: stood at $727.5 million in 2022, then declined by 27.83% to $525.0 million in 2023, then slipped by 10.89% to $467.8 million in 2024, then declined by 29.18% to $331.3 million in 2025, then declined by 8.87% to $301.9 million in 2026.
- The last three Assets Average figures came in at $301.9 million (Q1 2026), $331.3 million (Q4 2025), and $357.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | 301.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 301.93 Mn |
| Dec 31, 2025 | 331.30 Mn |
| Sep 30, 2025 | 357.65 Mn |
| Jun 30, 2025 | 385.15 Mn |
| Mar 31, 2025 | 419.68 Mn |
| Dec 31, 2024 | 467.83 Mn |
| Sep 30, 2024 | 511.89 Mn |
| Jun 30, 2024 | 549.35 Mn |
| Mar 31, 2024 | 538.05 Mn |
| Dec 31, 2023 | 525.00 Mn |
| Sep 30, 2023 | 564.27 Mn |
| Jun 30, 2023 | 607.55 Mn |
| Mar 31, 2023 | 667.95 Mn |
| Dec 31, 2022 | 727.46 Mn |
| Sep 30, 2022 | 778.20 Mn |
| Jun 30, 2022 | 832.72 Mn |
| Mar 31, 2022 | 889.92 Mn |
| Dec 31, 2021 | 953.01 Mn |
| Sep 30, 2021 | 1.00 Bn |
| Jun 30, 2021 | 1.03 Bn |